Foundayo for Weight Loss: What to Know About Eli Lilly’s New Oral GLP-1 Pill

What Is Foundayo?

Foundayo is the new Eli Lilly weight loss pill. It’s the brand name for orforglipron, a prescription oral GLP-1 receptor agonist, and was approved by the FDA in April 2026 for chronic weight management in adults.

The FDA-approved indication covers adults with obesity (a BMI of 30 or higher), as well as adults with overweight (a BMI of 27 or higher) who also have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol. 

Foundayo is intended to be used alongside a reduced-calorie diet and increased physical activity, meaning it’s not a standalone fix. It also shouldn’t be used with other GLP-1 receptor agonist medications.

‍

How Orforglipron Works: The Science in Plain Language

So, how exactly does Foundayo help with weight management? And what makes it different from other weight loss solutions? Let’s start with some basics.

‍

What Is a GLP-1 Receptor Agonist?

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after you eat. 

So, then, what is a GLP-1 medication?

A GLP-1 medication is a GLP-1 receptor agonist that mimics the action of GLP-1. By binding to GLP-1 receptors in the brain and gut, these medications may reduce appetite, slow gastric emptying (the rate at which food leaves your stomach), and help promote feelings of fullness. 

In fact, injectable GLP-1 medications, including semaglutide (Ozempic® and Wegovy®) and tirzepatide (Mounjaro® and Zepbound®), work through this same general pathway.

‍

What Makes Orforglipron Different: The Non-Peptide Distinction

Most GLP-1 receptor agonists are peptide-based, meaning they’re protein-derived molecules that can’t survive the digestive process intact. And this is why they’re usually injected.

Orforglipron, on the other hand, is a non-peptide small molecule. In other words, its chemical structure is different, and it’s stable enough to be absorbed through your digestive tract as a standard tablet. 

Foundayo is the first oral GLP-1 pill approved with labeling that allows it to be taken at any time of day, without food or water restrictions. This is distinct from other options, such as Rybelsus® (oral semaglutide), which requires a roughly 30-minute fasting window and limits water intake before dosing.

‍

What the Clinical Evidence Shows

Foundayo’s approval was supported by Eli Lilly’s ATTAIN trial program, a series of 72-week studies. The numbers below are derived from controlled clinical settings, achieved alongside a reduced-calorie diet and increased physical activity.

Among adults without type 2 diabetes (from an average starting weight of roughly 227 lbs):

• 5.5 mg dose: average weight loss of about 7.4% (~17.2 lbs)
• 9 mg dose: average weight loss of about 8.3% (~18.9 lbs)
• 17.2 mg dose: average weight loss of about 11.1% (~24.9 lbs)
• Placebo: average weight loss of about 2.1% (~5.3 lbs)

Among adults with type 2 diabetes:

• 5.5 mg dose: average weight loss of about 5.1% (~11.7 lbs)
• 9 mg dose: average weight loss of about 7.0% (~15.9 lbs)
• 17.2 mg dose: average weight loss of about 9.6% (~21.2 lbs)
• Placebo: average weight loss of about 2.5% (~5.9 lbs)

At the same time, individual results may vary. Ultimately, a licensed healthcare provider can help you understand what outcomes may be realistic for your individual situation.

‍

Who May Be a Candidate for Foundayo?

Candidacy is always determined by a licensed provider. The starting point is usually BMI, which is a screening measure based on your height and weight. 

FDA approval includes adults with a BMI of 30 or higher (obesity), as well as adults with a BMI of 27 or higher (overweight) who also have at least one weight-related condition. If you’re curious, you can check your BMI with our BMI calculator.

The weight-related conditions that may qualify you in the overweight category include high blood pressure, type 2 diabetes, high cholesterol or dyslipidemia, obstructive sleep apnea, and cardiovascular disease.

But Foundayo isn’t appropriate for everyone in these categories. It shouldn’t be taken by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). And it should never be combined with other GLP-1 receptor agonist medications. If you’re pregnant or breastfeeding, discuss your options with a licensed healthcare provider to determine what’s appropriate for your specific situation.

Ultimately, eligibility comes down to a licensed healthcare provider reviewing your full health history, current medications, and goals. You may be a candidate if you meet the clinical criteria, but the decision comes down to your provider and their assessment of what’s best for you.

‍

Potential Side Effects and Safety Considerations

Like other GLP-1s, Foundayo comes with a few common side effects and safety considerations.

Common Side Effects

The most frequently reported side effects in clinical trials were gastrointestinal, including:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite (which is also part of the intended mechanism)

These side effects tend to be most pronounced during dose escalation and may improve over time as your body adjusts. If symptoms are persistent or severe, talk with your provider; don’t stop any medication without first discussing it with your prescribing physician.

‍

Important Safety Warnings

In studies with rodents, orforglipron and medicines that work in a similar way caused thyroid tumors, including thyroid cancer. But it’s not currently known whether Foundayo causes thyroid tumors or medullary thyroid carcinoma (MTC) in humans. 

However, it’s important to inform your provider right away if you notice a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Additionally, as previously mentioned above, Foundayo shouldn’t be used with other GLP-1 receptor agonists, and individuals with a personal or family history of MTC or MEN 2 shouldn’t take it. Be sure to disclose all of your current medications and health conditions to your provider before starting.

‍

How Foundayo Compares to Injectable GLP-1 Options

With the above table in mind, it’s worth noting that the higher average weight loss seen with injectable tirzepatide (about 20.9% in the SURMOUNT-1 trial) and semaglutide (about 14.9% in the STEP 1 trial) doesn’t automatically make them the right choice for everyone. Factors including injection tolerance, dosing convenience, how your body responds, your other health conditions, and cost all play a role in what makes the most sense for you.

A licensed provider is the best resource to determine the next best step for you; they can perform a thorough evaluation and assess your health history before making any recommendations. 

‍

What to Discuss With Your Provider Before Starting Foundayo

When talking with your provider, make sure to bring up:

• Current medications: Some may interact with Foundayo or overlap with its mechanism.
• Personal and family health history: Thyroid conditions, a history of pancreatitis, kidney disease, and cardiovascular history are all relevant.
• Your goals and timeline: Your provider can help set realistic expectations based on your starting point and health profile.
• The dose escalation schedule: Foundayo uses titration, starting low and increasing gradually to ease common gastrointestinal side effects. In some cases, GLP-1 microdose schedules may also be considered.
• Diet and activity plan: Since Foundayo is approved as an adjunct to a reduced-calorie diet and physical activity, ask what lifestyle changes your provider expects alongside it. 
• Cost and coverage: As a brand-name prescription, pricing varies; discuss insurance, manufacturer savings programs, and self-pay options with your provider or pharmacist.

If getting to an in-person appointment feels like a hurdle or involves lengthy wait times, telehealth platforms may make this conversation more accessible.

‍

Exploring Your Options for Medically Guided Weight Loss

If you’re exploring GLP-1 options—whether Foundayo, injectable semaglutide, tirzepatide, or another approach—the most important step is connecting with a licensed provider who can evaluate your full picture.

Foundayo is just one option in the GLP-1 landscape, and the right medication depends on your individual health profile, your preference for oral versus injectable, your goals, and your clinical suitability. Across the board, medically supervised programs that combine provider oversight, ongoing monitoring, and support may help patients stay engaged with their treatment plan and weight-management goals. 

With Eden, we connect you with a licensed healthcare provider. From there, your provider will perform a thorough assessment and determine which program, such as compounded semaglutide or tirzepatide injections, may be right for you. (Note: Compounded medications are not FDA-approved and may be prescribed only when clinically appropriate.) Our process starts with a brief online intake.